Loss of PCAF has already been described in pancreatic cancer, endometrial tumors or head and neck carcinomas, and has been implicated in different molecular processes regulating tumor initiation and/or progression [23–25]. This evidence concerns the gene KAT2B and familial pancreatic carcinoma.